Tuesday, 23 October 2018

Roche lands Tecentriq trial win, still trails Merck in lung cancer

/ by  / in / with No comments /

Roche's Tecentriq plus chemotherapy boosted lung cancer patients' survival by nearly five months, study data released on Monday showed, underscoring benefits of the Swiss group's immunotherapy but still leaving it trailing a rival's drug.


from Reuters: Science News https://ift.tt/2S7VIXI
//

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)